食管和贲门早期浅表癌内镜Nd：YAG激光治疗五年存活率和预后因素

对内镜Ｎｄ：ＹＡＧ激光治疗后癌细胞消失的３２例食管和贲门早期清表癌病人进行了３３－７８个月的前瞻性随访。应用Ｐｒｏｄｕｃｔ Ｌｉｍｉｔ Ｅｓｔｉｍａｔｅ方法计算其存活率；并与１１７例食管和贲门早期浅表癌的自然病程进行了对比分析。     

内镜掺钕钇铝石榴石激光治疗食管和贲门早期浅表癌

内镜掺钕钇铝石榴石激光治疗食管和贲门早期浅表癌赵立群，王玉梅，杨观瑞，李珊珊，贾建红１９８９年４月～１９９３年１２月，在河南省食管癌高发区普查确诊的早期食管癌和贲门癌中，３３例接受了内镜掺钕钇铝石榴石（简称Ｎｄ：ＹＡＧ）激光治疗，其中２７例为食管早期...     

河南省1996年肿瘤研究新进展

一、内镜Nd：YAG激光治疗食管和责门早期浅表癌的研究河南省医学科学研究所杨观瑞教授等在Nd：YAG激光照射人食管组织效应实验研究的基础上，对对例食管和贲门早期浅表癌进行了内镜Nd：YAG激光介入治疗和l（y－x个月的前瞻性随访，同时对早期食管癌和贲门癌的技术指标、远期疗效和影响预后的因素进行了长期、系统的研究。结果表明：内镜Nd：YAG激光照射人食管癌组织当产生灰白色凝固斑时可引起癌组织凝固性坏死，食管粘膜层和粘膜肌层缺损，粘膜下层凝固性坏死，而肌层纤维无明显损伤，证明对早期癌可以起到安全有效的治疗作用。对原…     

35岁以下青年食管贲门癌181例诊治分析

１９８１年１月至１９９２年１２月间，我们共治疗食管贲门癌３４６７例，其中３５岁以下青年食管贲门癌１８１例，占同期手术病例的５．２４％（１８１／３４６７）。手术切除率９０％，并发症发生率６．８％（１１／１８１），手术死亡率１．１％（２／１８１）。术后１、３、５、１０年生存率分别为９８．５％、３９．６％、２７．５％、１２．３％，综合治疗远期生存率，３、５、１０年为４２．３％、３０．６％、１３．１％。本文提示：提高远期生存率的关键在于早期确诊，尽早治疗及术后放疗、化疗的配合。     

60例次YAG激光治疗膀胱癌临床观察

我科从１９８９－１９９１年Ｎｄ－ＹＡＧ激光治疗膀胱肿瘤６０例次，随防时间４－２８个月。１例局部复发（３％），８例其它部位复发（２８％）。３４例病人均未见穿孔、大出血合并症。激光治疗安全，适用于有选择性的膀胱肿瘤病人。     

阴道癌综合治疗46例分析

目的 探讨放疗、化疗、激光治疗等综合治疗措施对阴道癌的疗效及其毒副作用。方法 １９８５年８月～１９９５年７月山东省肿瘤医院收治４６例原发性阴道癌患者，全部采用＾５０Ｃ。体外照射加人后装治疗，１２例先以ＶＰＣ方案化疗两个周期，４例因局部病灶较大，采用ＹＡＧ激光治疗后行化疗和放疗。结果 所有病例均随访３年以上，４６例病人Ⅱ、Ⅲ期的３年生存率分别为６６．７％（４／６）、５５．０％（２２／４０），５年生存     

掺钕钇铝石榴石激光局部照射加全膀胱光动力疗法治疗膀胱癌

应用掺钕钇铝石榴石（简称Ｎｄ：ＹＡＧ）激光局部照射加全膀胱光动力疗法（ＰＤＴ）治疗膀胱移行上皮癌患者２０例，共５１个肿瘤，治愈率达９５％。疗后随诊３～２３个月，其肿瘤复发率为１０％。结果提示：Ｎｄ：ＹＡＧ激光可有效地消除膀胱的局部肿瘤，且可加强光动力疗法对局部肿瘤的作用；而全膀胱光动力疗法又可补充Ｎｄ：ＹＡＧ激光膀胱潜在病变控制的不足，有效地消除全膀胱的散在微小病灶，进而提高膀胱癌的治愈率，减少其复发率。     

内镜诊断青年人食管贲门癌11例分析

内镜诊断青年人食管贲门癌１１例分析闫维勤肥城市人民医院（２７１６００）我院自１９８７年３月至１９９４年３月，用胃镜共检出食管贲门癌３９２例，其中３５岁以下青年人食管贲门癌１１例，占同期食管贲门癌总数的２．８％。由于对青年人食管贲门癌的认识不够，误诊率...     

35岁以下青年食管贲门癌181例诊治分析

１９８１年１月至１９９２年１２月间，我们共治疗食管贲门癌３４６７例，其中３５岁以下青年食管贲门癌１８１例，占同期手术病例的５．２４％（１８１／３４６７）。手术切除率９０％，并发症发生率６．８％（１１／１８１），手术死亡率１．１％（２／１８１）。术后１、３、５、１０年生存率分别为９８．５％、３９．６％、２７．５％、１２．３％，综合治疗远期生存率，３、５、１０年为４２．３％、３０．６％、１３．１％。本     

同时性食管贲门重复癌34例报告

１９７６年１月至１９９４年１２月，我们收治同时性食管贲门重复癌３４例，占同期食管、贲门癌病人的０．７％（３４／５０４０）。全组食管病变全部为鳞癌，贲门病变中腺癌３２例、恶性纤维组织细胞瘤和平滑肌肉瘤各１例。术前诊断率７０．６％（２４／３４），手术切除率７９．４％（２７／３４），术后１、３、５年生存率分别为８７．５％（２１／２４）、４５．０％（９／２０）和１８．８％（３／１６）。作者认为：注意各项检查的相互配合及仔细的上消化道全面检查能提高诊断率，早期手术并扩大手术范围可提高手术疗效。     

老年食管瘤和贲门癌合并心电图异常外科治疗83例分析

评价老年食管癌和贲门癌合并心电图异常对外科手术的影响。方法：作者经手术治疗65岁以上老年食管癌和贲门癌共138例，其中术前合并心电图异常者83例，占60．1％（83／138）；术前除左束支传导阻滞、广泛性心肌供血不足、陈旧性及亚急性心肌梗塞患者给予7－10天心脏保护性药物治疗外，余均未作任何特殊性治疗。结果：术后共发生井发症9例次，占10．8％（9／83），其中心跳骤停1例次，急性心肌梗塞1例次，重度房颤2例次，胸胃局灶性坏死穿孔5例次，均经抢救性（和／或手术）治疗痊愈，本组无死亡者。结论：老年食管癌和贲门癌患者合并心电图异常，并不一定是心功能异常，并不一定影响外科手术治疗。     

Results of the treatment of children with recurrent gliomas with lomustine and vincristine

Gliomas comprise over 50% of all childhood brain tumors. Treatment of recurrent childhood gliomas has been disappointing and the effectiveness of therapy has been difficult to judge because of the variable natural history of the disease. Information gathered recently has suggested that treatment with [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea)] (CCNU) and vincristine (VCR) after radiotherapy is effective in prolonging survival in children with newly diagnosed anaplastic gliomas. The authors have used these same drugs--CCNU (100 mg/m2) and VCR (1.5 mg/m2 up to a maximum dose of 2 mg)--in 6-week cycles for a maximum of eight cycles in children with recurrent gliomas. To date, 15 patients have been treated; five patients had malignant gliomas and ten low-grade gliomas. Three children showed improvement, five had stable disease, and seven had progressive disease. Of the five patients with malignant gliomas, four progressed within two cycles of treatment and one had stable disease for 7 months on treatment and then relapsed. Seven of ten children with low-grade gliomas benefitted from treatment and six remain in continuous remission a median of 16 months after initiation of therapy. Three of these children are off all therapy 21, 30, and 30 months after treatment, respectively. Therapy was well tolerated and toxicity consisted primarily of reversible bone marrow suppression. The authors conclude that CCNU and VCR chemotherapy is effective in children with recurrent low-grade gliomas and can result in relatively long-term disease stabilization. In limited experience of the authors, it is not of benefit in children with recurrent anaplastic lesions.     

Staging and evaluation of the patient with lymphoma

Patients who have non-Hodgkin's lymphoma or Hodgkin lymphoma most often present for medical attention because of signs or symptoms referable to enlarged lymph nodes or other disease-related symptoms (such as fevers, night sweats or fatigue). Less often, enlarged lymph nodes or splenomegaly may be incidental findings during evaluation for other medical issues. Determination of the extent of disease and accurate assessment of responses are necessary for appropriate management. Newer technologies have improved the ability to evaluate patients and to conduct clinical trials, leading to more effective therapies. This article addresses the advances in staging and evaluation of patients who have lymphoma, specifically examining the use of positron emission tomography.     

肝细胞癌病人自身抗体的检测分析

用间接免疫荧光法检测了资料较全的77例肝细胞癌病人血清中的三种自身抗体:抗核抗体(ANA)、抗平滑肌抗体(SMA)和抗线粒体抗体(AMA)。发现不论是在Ⅰ期、Ⅱ期和Ⅲ的肝细胞癌病人ANA和SMA均明显增高;而肝硬化病人的AMA高于肝细胞癌患者,这对于指导临床诊断和治疗以及预后判断有一定的参考价值。     

Invivo control of tumor-growth with the association of ionidamine with radiation and or hyperthermia

The effect of lonidamine (LND) in association with fractionated doses of radiation and/or hyperthermia on tumor growth has been evaluated. The results may be summarized as follows: (i) the fractionation of the radiation dose, in spite of the higher dose delivered (20 Gy) does not increase tumor growth delay when compared to that obtained with a single irradiation treatment. A similar behaviour was also found when the fractionated irradiation was associated with LND. (ii) Hyperthermia is less effective than radiation in controlling tumor growth, but its effect is potentiated by LND although to a lesser extent that with radiation. (iii) LND delivered together with hyperthermia and radiation arrests tumor growth, and leads to the disappearance of the tumor in 75% of mice. The possible mechanisms underlying these effects are discussed.